Bladder instillation study for high-grade non–muscle-invasive cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This Phase 2 trial tests TARA-002 given directly into the bladder to treat high-grade non–muscle-invasive bladder cancer with active disease. It may help patients who have not previously responded to, or have not received, BCG treatment in the recent past.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older when you sign consent
- Have a confirmed diagnosis of high-grade carcinoma in situ (CIS) with possible Ta/T1, and active disease now
- Be either BCG naive, or have had BCG but not received bladder BCG for at least 24 months before your latest CIS diagnosis (or be BCG unresponsive)
- Have no evidence of cancer spread to lymph nodes or other organs now or at any time in the past
- Not have certain cancer types in the bladder (variant histology) or cancer involving the prostate or upper urinary tract
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study medicine called PF-08052667 for people with a certain type of bladder cancer that hasn't spread into the muscle. It's for those who have already tried BCG treatment and can't or won't have their bladder removed.
This study tests an immunotherapy drug (toripalimab) alone or followed by medication placed directly into the bladder (gemcitabine and mitomycin C) for people with high-risk bladder cancer that has not spread into the muscle wall and that has not responded to or couldn't be handled with BCG therapy. The goal is to see which approach works better.
This trial tests a combination of chemotherapy placed directly into the bladder and an immunotherapy drug called pembrolizumab (given through a vein) for people with high-risk bladder cancer that has not completely responded to or has returned after BCG treatment.
This trial tests radiotherapy (high-energy X-rays) for a specific type of early-stage bladder cancer (CIS) that hasn't gone away after BCG treatment. It's for people who can't or choose not to have bladder removal surgery.
This trial tests a new drug, 2141-V11, for people with bladder cancer that has not gone away after standard treatments like BCG therapy. It may help those with non-muscle invasive bladder cancer or, in one group, muscle-invasive bladder cancer, who cannot have or choose not to have bladder removal surgery.
This trial compares a new medicine called TARA-002, given directly into the bladder, to the doctor's choice of standard chemotherapy. It is for people with a high-grade, non-muscle invasive bladder cancer that has not been treated with BCG or has not had BCG recently.
Hear when a new Non Muscle Invasive Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.